Cardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure.
GSK-partnered Merck is throwing in the towel for a Phase II trial of its immunotherapy contender bintrafusp alfa after disappointing results.
UK-based start-up Beckley Psytech has completed an upsized Series B financing, raising €68m (US$80m). Proceeds will go towards the company’s pipeline of psychedelic compounds dedicated to addressing neurological and psychiatric disorders.
ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.
Setback for CureVac: Boehringer Ingelheim halts a 7-year-old €500m lung cancer collaboration with the Tübingen-based biopharmaceutical company.
Vaccine maker Valneva SE announced the initiation of a further Phase III trial for its COVID-19 vaccine candidate VLA2001.
Visus Therapeutics has baged a €20m stock financing to advance development of Brimochol for presbyopia
The protein eIF4A3 may hold the key for future cancer treatments, Karolinska researchers find.
British drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration.
The big pharma company is shelling out US$1.5bn in the acquisition of US screening specialist Vividion Therapeutics.